
Quarterly report 2025-Q3
added 11-14-2025
ENDRA Life Sciences Net Debt 2011-2026 | NDRA
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt ENDRA Life Sciences
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.37 M | -8.78 M | -6.54 M | -5.47 M | -6.47 M | -5.6 M | 805 K | -19.1 K | -156 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 805 K | -8.78 M | -4.07 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Diagnostics research industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Anixa Biosciences
ANIX
|
-1.04 M | $ 2.85 | -3.72 % | $ 92.5 K | ||
|
Centogene N.V.
CNTG
|
1.18 M | - | -6.23 % | $ 30.6 M | ||
|
Agilent Technologies
A
|
1.24 B | $ 118.6 | 0.4 % | $ 36.1 B | ||
|
Aspira Women's Health
AWH
|
-10.9 M | - | -6.19 % | $ 10.5 M | ||
|
Celcuity
CELC
|
82.8 M | $ 107.62 | -0.63 % | $ 4.25 B | ||
|
Fulgent Genetics
FLGT
|
-53.3 M | $ 13.82 | -2.68 % | $ 418 M | ||
|
Akumin
AKU
|
1.21 B | - | -17.87 % | $ 25.9 M | ||
|
Castle Biosciences
CSTL
|
-108 M | $ 27.55 | -1.59 % | $ 765 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
-173 M | - | - | $ 562 M | ||
|
Heska Corporation
HSKA
|
-153 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-11.2 M | - | -20.0 % | $ 1.06 M | ||
|
Charles River Laboratories International
CRL
|
1.98 B | $ 175.77 | -1.61 % | $ 8.71 B | ||
|
ICON Public Limited Company
ICLR
|
4.63 B | $ 108.44 | 0.16 % | $ 8.94 B | ||
|
IDEXX Laboratories
IDXX
|
222 M | $ 635.29 | -0.22 % | $ 51.1 B | ||
|
Accelerate Diagnostics
AXDX
|
-33.3 M | - | -61.36 % | $ 2.46 M | ||
|
Global Cord Blood Corporation
CO
|
-6.07 B | - | - | $ 399 M | ||
|
Laboratory Corporation of America Holdings
LH
|
4.74 B | $ 283.19 | -1.07 % | $ 23.6 B | ||
|
Fluidigm Corporation
FLDM
|
-5.38 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-11.1 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-1.35 B | - | 0.12 % | $ 80.1 M | ||
|
Lantheus Holdings
LNTH
|
213 M | $ 79.15 | 3.74 % | $ 5.34 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
769 M | - | - | $ 10.7 B | ||
|
Motus GI Holdings
MOTS
|
-3.55 M | - | -34.28 % | $ 263 K | ||
|
Mettler-Toledo International
MTD
|
2.06 B | $ 1 315.61 | -0.56 % | $ 27.1 B | ||
|
Biodesix
BDSX
|
14.5 M | $ 15.5 | -1.59 % | $ 2.01 B | ||
|
Myriad Genetics
MYGN
|
115 M | $ 5.26 | 4.89 % | $ 487 M | ||
|
NeoGenomics
NEO
|
187 M | $ 9.53 | 0.26 % | $ 1.22 B | ||
|
Biocept
BIOC
|
-11.2 M | - | -13.05 % | $ 7.29 M | ||
|
National Research Corporation
NRC
|
30.1 M | $ 13.37 | -3.47 % | $ 328 M | ||
|
Natera
NTRA
|
-177 M | $ 206.39 | 3.11 % | $ 20.3 B | ||
|
Invitae Corporation
NVTA
|
-239 M | - | - | $ 21.2 M | ||
|
BioNano Genomics
BNGO
|
-2.64 M | $ 1.12 | -1.78 % | $ 1.42 M | ||
|
Quest Diagnostics Incorporated
DGX
|
4.92 B | $ 208.28 | -0.95 % | $ 23.1 B | ||
|
Danaher Corporation
DHR
|
14 B | $ 204.04 | -0.9 % | $ 145 B | ||
|
Organovo Holdings
ONVO
|
-10.4 M | - | -2.3 % | $ 19.4 M | ||
|
OPKO Health
OPK
|
-411 M | $ 1.22 | -2.02 % | $ 847 M | ||
|
Pacific Biosciences of California
PACB
|
-6.67 M | $ 1.51 | -7.1 % | $ 453 M | ||
|
Exact Sciences Corporation
EXAS
|
-916 M | $ 103.38 | 0.02 % | $ 19.5 B | ||
|
Bioventus
BVS
|
334 M | $ 8.8 | 0.34 % | $ 551 M | ||
|
DarioHealth Corp.
DRIO
|
-12.1 M | $ 10.3 | -4.19 % | $ 292 M | ||
|
DexCom
DXCM
|
-842 M | $ 73.0 | -1.06 % | $ 28.5 B | ||
|
PerkinElmer
PKI
|
2.3 B | - | -0.91 % | $ 14.7 B | ||
|
Psychemedics Corporation
PMD
|
-3.41 M | - | -1.84 % | $ 15.3 M | ||
|
Precipio
PRPO
|
-1.18 M | $ 24.78 | 0.38 % | $ 32.2 M | ||
|
QIAGEN N.V.
QGEN
|
1.31 B | - | - | $ 10.6 B | ||
|
Quotient Limited
QTNT
|
103 M | - | -11.32 % | $ 1.1 M | ||
|
Burning Rock Biotech Limited
BNR
|
-76 M | $ 24.01 | -4.59 % | $ 254 M | ||
|
Illumina
ILMN
|
-494 M | $ 129.9 | -2.25 % | $ 20.7 B | ||
|
Renalytix AI plc
RNLX
|
24.5 K | - | 5.66 % | $ 22.7 M | ||
|
VolitionRx Limited
VNRX
|
910 K | $ 0.2 | -0.74 % | $ 19.2 M |